MedPath

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Laquinimod Phase IIa Study in Active Crohn's Disease

Phase 2
Completed
Conditions
Crohn's Disease
Interventions
Other: placebo
First Posted Date
2008-08-20
Last Posted Date
2015-03-20
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
180
Registration Number
NCT00737932
Locations
🇧🇪

Teva Investigational Site 3711, Bonheiden, Belgium

🇧🇪

Teva Investigational Site 3712, Leuven, Belgium

🇧🇪

Teva Investigational Site 3713, Roeselare, Belgium

and more 31 locations

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

Phase 2
Completed
Conditions
Huntington Disease
Interventions
Other: Placebo
First Posted Date
2008-07-29
Last Posted Date
2023-08-31
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
227
Registration Number
NCT00724048
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of California, San Diego, California, United States

🇺🇸

Colorado Neurological Institute, Littleton, Colorado, United States

and more 25 locations

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
ALS
Interventions
Other: placebo
First Posted Date
2008-06-12
Last Posted Date
2011-10-21
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
559
Registration Number
NCT00696332
Locations
🇺🇸

CA Medical Center for Movement Disorders-Forbes Norris MDA/ALS Research Center, San Francisco, California, United States

🇺🇸

University of Kansas Medical Center - Dept of Neurology, Kansas City, Kansas, United States

🇺🇸

Johns Hopkins OPC - Meyer Bldg, Baltimore, Maryland, United States

and more 21 locations

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

Phase 3
Completed
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2008-04-24
Last Posted Date
2012-06-25
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
481
Registration Number
NCT00666224

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

Phase 3
Completed
Conditions
Huntington's Disease
Interventions
Drug: Placebo
First Posted Date
2008-04-23
Last Posted Date
2023-08-29
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
437
Registration Number
NCT00665223
Locations
🇦🇹

LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz, Graz, Styria, Austria

🇦🇹

Innsbruck Medical University, Anichstraße 35, Innsbruck, Tyrol, Austria

🇧🇪

University Hospital Gasthuisberg, Leuven, Flemish Brabant, Belgium

and more 28 locations

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Phase 3
Completed
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2008-01-30
Last Posted Date
2022-04-21
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1331
Registration Number
NCT00605215
Locations
🇺🇸

Teva Investigational Site 1267, Birmingham, Alabama, United States

🇺🇸

Teva Investigational Site 1237, Phoenix, Arizona, United States

🇺🇸

Teva Investigational Site 1252, Phoenix, Arizona, United States

and more 167 locations

Albuterol HFA MDI in Pediatric Participants With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
First Posted Date
2007-12-20
Last Posted Date
2021-11-12
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
103
Registration Number
NCT00577655
Locations
🇺🇸

Pediatric Care Medical Group, Inc., Huntington Beach, California, United States

🇺🇸

California Allergy & Asthma Medical Group, Palmdale, California, United States

🇺🇸

Center for Clinical Trials, LLC, Paramount, California, United States

and more 10 locations

A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021

Phase 3
Completed
Conditions
Healthy
Interventions
Drug: DR-1021
Drug: Mircette®
Drug: Kariva®
First Posted Date
2007-10-16
Last Posted Date
2021-11-18
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
61
Registration Number
NCT00544882
Locations
🇺🇸

Duramed Investigational Site, Seattle, Washington, United States

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: Albuterol-HFA-BAI
Drug: Albuterol-HFA-MDI
First Posted Date
2007-09-17
Last Posted Date
2022-09-07
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
49
Registration Number
NCT00530062
Locations
🇺🇸

Clinical Study Site, Lake Oswego, Oregon, United States

🇺🇸

Teva Clinical Study Site, Lakewood, Colorado, United States

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 3
Completed
Conditions
Multiple Sclerosis
Interventions
Other: Placebo
First Posted Date
2007-07-31
Last Posted Date
2021-11-02
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1106
Registration Number
NCT00509145
Locations
🇺🇸

Teva Investigational Site 1076, Phoenix, Arizona, United States

🇺🇸

Teva Investigational Site 1090, Centennial, Colorado, United States

🇺🇸

Teva Investigational Site 1088, Fort Collins, Colorado, United States

and more 141 locations
© Copyright 2025. All Rights Reserved by MedPath